Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income towards Common Stockholders (2016 - 2025)

Ultragenyx Pharmaceutical has reported Net Income towards Common Stockholders over the past 10 years, most recently at -$128.6 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 4.21% to -$128.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$575.0 million through Dec 2025, down 0.88% year-over-year, with the annual reading at -$575.0 million for FY2025, 0.88% down from the prior year.
  • Net Income towards Common Stockholders was -$128.6 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$180.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $485.4 million in Q4 2023 and troughed at -$245.1 million in Q3 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$143.6 million (2021), against an average of -$92.5 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 1284.5% in 2021 against a maximum downside of 583.62% in 2021.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $332.9 million in 2021, then crashed by 146.11% to -$153.5 million in 2022, then surged by 416.31% to $485.4 million in 2023, then crashed by 127.64% to -$134.2 million in 2024, then increased by 4.21% to -$128.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Net Income towards Common Stockholders are -$128.6 million (Q4 2025), -$180.4 million (Q3 2025), and -$115.0 million (Q2 2025).